Affymax/Takeda confirm US filing plans of anaemia drug Hematide
This article was originally published in Scrip
Executive Summary
Affymax/Takeda have confirmed that they plan to file their investigational erythropoiesis-stimulating agent (ESA), Hematide (peginesatide), with the US FDA in the second quarter of next year for the treatment of anaemia in chronic renal failure patients on dialysis.